Minnesota Oncology and Virginia Piper Cancer Institute in Minneapolis are seeking participants for a study aiming to try to better understand, prevent and improve "chemo brain." (What is chemo brain?)
They will begin enrolling subjects on Monday, February 22 in the new study, called Focus Forward Cognitive PreHab.
To be considered for the study, patients must meet the following criteria:
- Have been diagnosed with breast cancer or ovarian cancer, which represents a first cancer diagnosis and not a recurrence
- Are scheduled to receive 1 of the following chemotherapy regimens for breast or ovarian cancer:
- Taxotere and cyclophosphamide (Cytoxan) (TC)
- Doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC)
- Adriamycin and cyclophosphamide (Cytoxan) followed by Taxol (AC-T)
- Taxotere, Carboplatin, Herceptin (TCH)
- Paclitaxel and Carboplatin (6 cycles)
- Be at least 18 years of age
- Speak English
- Be able to see and hear (with or without correction/hearing device)
Exclusion criteria:
- Untreated/unstable psychiatric disorder
- Known cognitive deficits from other conditions, including metastases to brain
To find out more about this study or apply to be a participant, contact Karen Swenson, PhD, RN (612-863-5658) or Mary Radomski, PhD, OTR/L (612-863-3291).
Share
Categories
Tags
Recent Posts
Popping a few burgers or steaks on the grill can be a fun and relaxing way to enjoy summer with family and friends, but some methods of grilling are riskier than others. Cooking with charcoal or cooking your meat incorrectly may be linked to an increased risk of cancer—but there’s no need to avoid the grill completely.
How Food Insecurity Can Affect Patients with Cancer. Surveys conducted in various locations throughout the United States showed that 17 to 55 percent of cancer patients are affected by food insecurity.
What’s Next? Transitioning to Follow-Up Care After Cancer Treatment. Transitioning to follow-up cancer care is a crucial part of your recovery, ensuring you stay healthy and empowered in the days to come.